NCT00488163View on ClinicalTrials.gov

Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

June 30, 2007

Conditions
Schizophrenia
Interventions
DRUG

Atomoxetine

Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.

Trial Locations (2)

10029

Mount Sinai Hospital, New York

11717

Pilgrim Psychiatric Center, Brentwood

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Research Foundation for Mental Hygiene, Inc.

OTHER

NCT00488163 - Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia | Biotech Hunter | Biotech Hunter